A Phase 3 interventional study of Esomeprazole in Heartburn, sponsored by AstraZeneca. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-11.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing esomeprazole in Heartburn — none open to participants now, none under way, none of them phase 3. Esomeprazole · Heartburn.
Among the 19 studies testing esomeprazole in Heartburn, this one is the 6th largest by enrollment, is one of 3 that started in 2011, is one of 3 in phase 3, and was the 16th registered.
154 studies on the registry are indexed under Heartburn; 12 are open to participants now.
Browse Heartburn studies →None of the 19 studies testing esomeprazole in Heartburn is open now. The open studies under Heartburn, anywhere →
Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 8 Heartburn studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2011.
This study's enrollment of 341 is above the median of 100 across 127 interventional studies indexed under Heartburn.
Median enrollment 248 across the 19 interventional studies. Of the 18 that completed or were terminated, 7 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 19 have an industry lead sponsor. The 5 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
24 studies in Heartburn by AstraZeneca: none open now, none under way, none of them phase 3. Of 24 finished, 8 (33%) have results posted.
Among the 24 studies in Heartburn by AstraZeneca, this one is the 7th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2011, is one of 3 in phase 3, and was the 22nd registered.
AstraZeneca’s Heartburn studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing esomeprazole in Heartburn, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 24 in Heartburn:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will investigate the efficacy of esomeprazole 20 mg once a day in the treatment of frequent heartburn
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Esomeprazole
Drug: Esomeprazole
Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
Percentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment
Time frame: From randomisation to day 14
Number of Subjects Reporting Heartburn 2 Days or Less During the 14 Days Randomized Treatment Period
Treatment period is considered to be both weeks 1 and 2 between V3 and V4.
Time frame: From randomisation to the day 14
Comparison of Number of Subjects With 0, 1, 2, 3 or 4 Days With no Heartburn Over Days 1 to 4 Between Esomeprazole 20 mg and Placebo
The first 4 consecutive days subjects were on randomized treatment, between V3 and V4.
Time frame: From randomisation to day 14
Number of Subjects With Heartburn 1 Day or Less During the Final Week, Second Week, First Week of Treatment
There were three separate 7 day time periods during the treatment period; The first week (days 1-7), the second week (days 8-14), and the last 7 consecutive days (last day subject reported and the prior 6). For a given subject, the second week and last 7 consecutive days are the same if the subject has recorded measurements for the entire 14 day treatment period. However, for subjects reporting anything less than 14 days the two will not be identical. For all three 7 day time periods, days when a subject did not call in (i.e., missing values) were imputed as a day with heartburn.
Time frame: From randomisation to day 14
From total of 526 screened subjects, 341 subjects were randomised. From 341 subjects 170 and 171 were allocated to Esomeprazole and Placebo respectively.
| Milestone | Esomeprazole | Placebo |
|---|---|---|
| Started | 170 | 171 |
| Patients who received treatment | 165 | 161 |
| Patients who completed treatment | 151 | 152 |
| Completed | 151 | 152 |
| Not completed | 19 | 19 |
| Withdrew: Voluntary discontinuation by subject | 3 | 2 |
| Withdrew: Eligibility criteria not fulfilled | 0 | 1 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Protocol violation | 8 | 5 |
| Withdrew: Development of study specific withdrawal | 1 | 1 |
| Withdrew: Lost to follow up | 6 | 10 |
| Percentage of heartburn free days | Esomeprazole | Placebo |
|---|---|---|
| Percentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment | 46.79 ± 33.32 | 30.93 ± 28.86 |
Treatment period is considered to be both weeks 1 and 2 between V3 and V4.
| Participants | Esomeprazole | Placebo |
|---|---|---|
| Number of Subjects Reporting Heartburn 2 Days or Less During the 14 Days Randomized Treatment Period | 27 | 2 |
The first 4 consecutive days subjects were on randomized treatment, between V3 and V4.
| Participants | Esomeprazole | Placebo |
|---|---|---|
| Zero days | 55 | 77 |
| One day | 32 | 34 |
| Two days | 22 | 29 |
| Three days | 37 | 16 |
| Four days | 16 | 2 |
There were three separate 7 day time periods during the treatment period; The first week (days 1-7), the second week (days 8-14), and the last 7 consecutive days (last day subject reported and the prior 6). For a given subject, the second week and last 7 consecutive days are the same if the subject has recorded measurements for the entire 14 day treatment period. However, for subjects reporting anything less than 14 days the two will not be identical. For all three 7 day time periods, days when a subject did not call in (i.e., missing values) were imputed as a day with heartburn.
| Participants | Esomeprazole | Placebo |
|---|---|---|
| Last 7 consecutive days | 40 | 17 |
| Second 7 calendar days | 38 | 13 |
| First 7 calendar days | 32 | 7 |
| Percentage of heartburn free days | Esomeprazole | Placebo |
|---|---|---|
| Percentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment | 47.82 ± 33.23 | 28.83 ± 31.22 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Esomeprazole | — | 0/162 (0%) | 18/162 (11.1%) |
| Placebo | — | 0/158 (0%) | 15/158 (9.5%) |
| Event | Esomeprazole | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 5/162 | 4/158 |
| ConstipationGastrointestinal disorders | 4/162 | 0/158 |
| DiarrhoeaGastrointestinal disorders | 4/162 | 3/158 |
| PainGeneral disorders | 0/162 | 3/158 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/162 | 0/158 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 3/162 | 1/158 |
| Dry mouthGastrointestinal disorders | 1/162 | 2/158 |
| VomitingGastrointestinal disorders | 0/162 | 2/158 |
| PyrexiaGeneral disorders | 0/162 | 2/158 |
| NasopharyngitisInfections and infestations | 2/162 | 2/158 |
| Age Continuous(Years) | Esomeprazole | Placebo | Total |
|---|---|---|---|
| All | 41.6 ± 14.0 | 42.8 ± 13.2 | 42.2 ± 13.6 |
| Sex: Female, Male(Participants) | Esomeprazole | Placebo | Total |
|---|---|---|---|
| Female | 91 | 87 | 178 |
| Male | 79 | 84 | 163 |
| Race/Ethnicity, Customized(Participants) | Esomeprazole | Placebo | Total |
|---|---|---|---|
| WHITE | 111 | 120 | 231 |
| BLACK OR AFRICAN AMERICAN | 52 | 50 | 102 |
| NATIVE HAWAIIAN/PACIFIC ISLANDER | 1 | 0 | 1 |
| AMERICAN INDIAN/ALASKA NATIVE | 3 | 0 | 3 |
| OTHER | 3 | 1 | 4 |
| Race/Ethnicity, Customized(Participants) | Esomeprazole | Placebo | Total |
|---|---|---|---|
| HISPANIC OR LATINO | 24 | 25 | 49 |
| NOT HISPANIC OR LATINO | 55 | 46 | 101 |
| NOT REPORTED | 91 | 100 | 191 |
The record gives a start of Aug 2011, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2013, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esomeprazole